INTERCEPT is not approved for sale in the United States and certain other countries.

SIGN UP FOR OUR
E-NEWSLETTER

INTERCEPT eNews delivers product news & information updates.

2009

2009 INTERCEPT Conference Abstracts

 

Jump to Conference
ISBT Cairo SFTS AABB
EHA IABs ISBT Nagoya
SETS DGTI  

 

XIXth Regional Congress International Society of Blood Transfusion (ISBT)
March 21 – 25, 2009 | Cairo, Egypt

  • Osselaer JC, Doyen C, Defoin L et al. A Two-Year Experience of Transfusing Platelet Components Prepared with INTERCEPT Pathogen Inactivation System and Stored for Up to 7 Days.Vox Sang 2009;96(Suppl 1):61-62.
     
  • Al-Radwan R, Al-Abdulrazzak R, Al-Shatti S et al. Standardization of Platelet Components Treated with INTERCEPT Pathogen Inactivation at Kuwait Central Blood Bank. Vox Sang 2009;96(Suppl 1):219.
    [Poster PDF]

     
  • Defoin L, Vandenbossche S, van Hooydonk M et al. Evaluation of in vitro Platelet Properties of Apheresis Platelets Collected in 100% Plasma Treated with INTERCEPT Blood System and Stored for Up to Nine Days. Vox Sang 2009;96(Suppl 1):221-222.
    [Poster PDF]
     
  • Lin L, Deane M, Rivera P et al. Treatment of Double Dose Platelet Components with the INTERCEPT Blood System and Subsequent Storage in Two Containers. Vox Sang 2009;96(Suppl 1):226-227.
    [Poster PDF]
     
  • L Sawyer, S Higgs, K Tsetsarkin, D Vanlandingham, R Johnson. Inactivation of Transfusion-Transmitted Vector Borne Pathogens. Vox Sang 2009;96(Suppl 1):233-234.
    [Poster PDF]
     
  • Cazenave JP, Osselaer JC, Waller C et al. An Active Hemovigilance Program Utilizing an EDC System to Assess Safety of 6359 Plasma Component Transfusions Prepared with the INTERCEPT Blood System. Vox Sang 2009;96(Suppl 1):208-209.
    [Poster PDF]
     
  • Castro E, Pajares AL, Barea LM et al. A New Tool for Increasing the Efficiency of INTERCEPT Pathogen Inactivation (PI) System for Plasma. Vox Sang 2009;96(Suppl 1):220-221.
    [Poster PDF]
     
  • Pinkoski L and Corash L. INTERCEPT Plasma Retains Coagulation Factor Activity when Prepared from Different Plasma Sources.  Vox Sang 2009;96(Suppl 1):231-232.
    [Poster PDF]
     
  • Erickson AC, Castri G, Waldhaus K et al.  Evaluation of in vitro Quality of Stored RBC after Treatment with the S-303 Treatment Process.
    [Poster PDF]
     
  • Hanson D, Mababangloob R, Patel N et al.  Bacterial and Viral Inactivation by the S-303 Treatment Process for Red Blood Cells (RBCs).
    [Poster PDF]

14th Annual Congress of the European Hematology Association (EHA)
June 4 - 7, 2009 | Berlin, Germany

  • Cazenave JP, Wiesel ML, Mendel I et al. Transfusion of Platelet Components Prepared with Photochemical Pathogen Inactivation for Support of Severe Glanzmann Thrombasthenia During Surgical Procedures.
    [Poster PDF]
     
  • Osselaer JC, Cazenave JP, Rasongles P et al on behalf of the INTERCEPT Platelet Hemovigilance Study Group. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with Photochemical Pathogen Inactivation Treatment Transfused In Routine Clinical Practice.
     
  • Cazenave JP, Mendel I, Waller C et al. Active Hemovigilance of Pediatric Patients Supported with Plasma Components Prepared with Amotosalen Plus UVA Photochemical Treatment.
    [Poster PDF]
     
  • Kientz D, Wiesel ML, Lanois I et al. Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) Using Plasma Prepared with Photochemical Pathogen Inactivation: A One Year Experience in Routine Practice in a Regional Blood Center.
    [Poster PDF]

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
June 11 - 13, 2009 | Tarragona, Spain

  • Girona-Llobera E, Jiménez-Marco ML, Sedeño M et al. Implantación en un centro de transfusión del sistema INTERCEPT de inactivatión de patógenos de componentes plaquetarios.
     
  • Girona-Llobera E, Jiménez-Marco ML, Sedeño M et al.  Impacto de la Inactivacion de Patogenos en la Caducidad de los Componentes Plaquetarios en un Centro de Transfusion.
     
  • Pajares A, Barea L, Rodriguez P et al.. Mejora en la eficiencia del sistema INTERCEPT para plasma mediante un dispositivo para mezclar 5 PFC.

XXIVth Congres de la Société Français de Transfusion Sanguine (SFTS)
June 22 - 25, 2009 | Strasbourg, France

  • Massard S, Civadier C, Ernou I et al. Mise en place du procede INTERCEPT sure le plasma au CTSA.
     
  • Kientz D, Lanois I, Bohbot A et al.  Comparaison de I'Efficacite des Echanges Plasmatiques par du Plasma Frais Congele Securise ou Apres Inactivation des Agents Pathogenes par la Technique Amotosalen-UVA, Etude Retrospective a I'EFS - Alsace.
     
  • Ohlmann P, Cazenave JP, Isola H et al.  Le Traitement Photochimique (Amotosalen + UVA) des Pathogenes Plasmatiques n'a pas d'Impact Majeur sur le Profil d'Expression Proteique Evalue par la Technique 2D-DIGE.
     
  • Wiesel ML, Boucher A, Isola H et al.  Evaluation Biologique a l'Aide du Thrombogramme des Capacites Hemostatiques du Plasma Apres Inactivation Photochimique des Pathogenes par Amotosalen et UVA.

6th International Association for Biologicals Symposium on Advances in Transfusion Safety (IABs)
July 6 -7, 2009 | Cambridge, UK

  • Lin L, Mufti N.  RBC Pathogen Inactivation of Red Blood Cell Concentrates (RBC) and Whole Blood (WB) Using the INTERCEPT Technology:  Advances and Challenges.

42nd Annual Congress of the German Society for Transfusion Medicine and Immunohaematology (DGTI)
September 15 - 18, 2009 | Rostock, Germany

  • Henschler R, Wiesneth M, Pfeiffer H et al. Double-Dose Platelet Concentrates Prepared from Pools of 7 or 6 Buffy Coats for Pathogen-Inactivation with the INTERCEPT System. Transfus Med Hemother 2009;36(suppl 1):1-6.
     
  • Deane M, Rivera P, Sawyer L.   INTERCEPT Platelets Treated and Stored in SSP+ Meet Council of Europe Standards for In Vitro function After 7 Days of Storage. Transfus Med Hemother 2009;36(suppl 1):1-62.
     
  • Lehmann C, Rummler S, Kummer C et al.  A New Cell Free, Pathogen Inactivated Single Donor Plasma. Transfus Med Hemother 2009;36(suppl 1):1-62.

2009 AABB Annual Meeting & TXPO
October 24 - 27, 2009 | New Orleans, LA, USA

  • Brilhante DP, Rodrigues S, Santos M et al. Platelet Components Treated with Pathogen Inactivation: Clinical Outcomes of the First Single Center Observational Study in Lisbon, Portugal. Transfusion 2009; 49(suppl 1):97A.
     
  • Rasongles P, Knutson F, Tardivel R et al.  Safety of Transfusions in Pediatric Patients with Platelet Components Prepared with Photochemical Treatment (INTERCEPT Blood System).
     
  • Girona-Llobera E, Jimenez-Marco TM, Sedeño M et al. The Impact of the Platelet Pathogen Inactivation Technology on the Platelet Inventory Management. Transfusion 2009; 49(suppl 1):266A.
     
  • Sawyer L, Mababangloob R, Patel N et al. Pathogen Inactivation Achieved with Amotosalen and UVA in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol. Transfusion 2009; 49(suppl 1):95A.
    [Poster PDF]

     
  • Isola H, Kientz D, Bigey F et al. The Impact of Replacing Quarantine Plasma by Plasma Prepared with Pathogen Inactivation (INTERCEPT™) – Experience in EFS-Alsace. Transfusion 2009; 49(suppl 1):81A.
    [Poster PDF]

XXth Regional Congress of the International Society of Blood Transfusion, Asia
November 14 - 18, 2009
| Nagoya, Japan

  • Lin L, Corash L.  An Active Hemovigilance Program to Characterize the Safety Profile of 16, 631 Platelet Components Prepared with INTERCEPT Blood System Transfused in Routine Clinical Practice.
    [Poster PDF]
     
  • Lin L, Shimosaka A, Osselaer JC.  Pathogen Inactivation and In Vitro Function of Platelet Components Collected in 100% Plasma Treated with INTERCEPT Blood System.
    [Poster PDF]
     
  • Cazenave JP, Kientz D, Waller C et al.  Active Hemovigilance of Pediatric Patients Supported With Plasma Components Prepared with Photochemical Treatment (INTERCEPT).
    [Poster PDF]
     

 

Untitled Document